{"id":"atazanavir-reyataz","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia (unconjugated)"},{"rate":"5-10","effect":"Jaundice"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"1-2","effect":"Nephrolithiasis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that binds to the active site of HIV protease, an enzyme essential for processing viral precursor proteins into functional components. By blocking this enzymatic activity, the drug prevents the formation of mature, infectious viral particles, thereby reducing viral replication and slowing disease progression. It is typically used as part of combination antiretroviral therapy (cART) in HIV-infected patients.","oneSentence":"Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:10.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT03194165","phase":"","title":"Population Pharmacokinetics of Antiretroviral in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-16","conditions":"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed","enrollment":65},{"nctId":"NCT01602822","phase":"PHASE4","title":"Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV","status":"TERMINATED","sponsor":"Kenneth H. Mayer, MD","startDate":"2012-02","conditions":"HIV","enrollment":11},{"nctId":"NCT02652793","phase":"NA","title":"Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2015-11","conditions":"Human Immunodeficiency Virus","enrollment":31},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT04121195","phase":"PHASE2, PHASE3","title":"Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2020-10-30","conditions":"HIV/AIDS, Tuberculosis","enrollment":26},{"nctId":"NCT04468087","phase":"PHASE2, PHASE3","title":"Antiviral Agents Against COVID-19 Infection","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2021-02-15","conditions":"COVID-19","enrollment":256},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT02542852","phase":"PHASE2","title":"A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia","status":"COMPLETED","sponsor":"Castagna Antonella","startDate":"2015-09","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT01511809","phase":"PHASE3","title":"Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2010-09","conditions":"HIV-1 Infection","enrollment":117},{"nctId":"NCT01620944","phase":"PHASE3","title":"Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07-31","conditions":"HIV","enrollment":3},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT04021290","phase":"PHASE3","title":"Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-11","conditions":"HIV Infections","enrollment":493},{"nctId":"NCT05680792","phase":"NA","title":"Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers","status":"COMPLETED","sponsor":"Obafemi Awolowo University","startDate":"2020-09-10","conditions":"Drug Interaction","enrollment":17},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT03923231","phase":"","title":"Pharmacokinetics of Atazanavir in Special Populations","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2019-09-02","conditions":"HIV/AIDS, Tuberculosis","enrollment":32},{"nctId":"NCT04184869","phase":"PHASE1","title":"Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2019-08-05","conditions":"Solid Tumor, Hematological Malignancies","enrollment":8},{"nctId":"NCT05236738","phase":"PHASE1","title":"A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-05-13","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT02457494","phase":"","title":"Kidney Stone Risk Factors in Patients Infected With HIV","status":"COMPLETED","sponsor":"Corinne Isnard Bagnis","startDate":"2015-05","conditions":"Nephrolithiasis, HIV","enrollment":23},{"nctId":"NCT04459286","phase":"PHASE2","title":"The Nitazoxanide Plus Atazanavir for COVID-19 Study","status":"TERMINATED","sponsor":"Obafemi Awolowo University","startDate":"2020-10-09","conditions":"Covid-19","enrollment":57},{"nctId":"NCT04452565","phase":"PHASE2, PHASE3","title":"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2022-06-15","conditions":"Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":525},{"nctId":"NCT02307656","phase":"PHASE1","title":"Taste Properties of Atazanavir and Cobicistat","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-12-12","conditions":"HIV in Adults","enrollment":6},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT04263350","phase":"PHASE1","title":"A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-02-26","conditions":"Healthy Participants","enrollment":34},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00006604","phase":"PHASE1, PHASE2","title":"Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections","enrollment":195},{"nctId":"NCT00084019","phase":"NA","title":"Atazanavir/Ritonavir Maintenance Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT00007202","phase":"PHASE2","title":"Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00096850","phase":"NA","title":"Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":18},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04385719","phase":"PHASE2","title":"Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2021-05-05","conditions":"Ebola, HIV/AIDS","enrollment":24},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT02431208","phase":"PHASE1","title":"A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-07-22","conditions":"Multiple Myeloma","enrollment":85},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02565888","phase":"PHASE1","title":"A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-11","conditions":"Hepatitis C, HIV","enrollment":16},{"nctId":"NCT02566707","phase":"PHASE2","title":"Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2015-08","conditions":"HIV-1 Infection","enrollment":9},{"nctId":"NCT00943540","phase":"PHASE2","title":"Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-07","conditions":"HIV Infection, HIV Infections","enrollment":20},{"nctId":"NCT03708861","phase":"PHASE3","title":"Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients","status":"WITHDRAWN","sponsor":"University of Turin, Italy","startDate":"2016-01","conditions":"HIV Infection","enrollment":""},{"nctId":"NCT04531072","phase":"PHASE4","title":"Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine","status":"COMPLETED","sponsor":"Fogarty International Center of the National Institute of Health","startDate":"2018-09-18","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00411957","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-01","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT01138267","phase":"","title":"Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2009-05","conditions":"HIV Infections","enrollment":450},{"nctId":"NCT00940771","phase":"PHASE4","title":"Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens","status":"COMPLETED","sponsor":"Phoenix Children's Hospital","startDate":"2009-08-26","conditions":"Pediatric HIV, HIV Infections","enrollment":10},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02652624","phase":"PHASE3","title":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-02-19","conditions":"HIV-1 Infection","enrollment":472},{"nctId":"NCT00718536","phase":"PHASE4","title":"Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-08","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00355719","phase":"PHASE4","title":"Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2007-01","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT01803074","phase":"PHASE2","title":"Study to Evaluate a HIV Drug for the Treatment of HIV Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-04-04","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":107},{"nctId":"NCT01388543","phase":"PHASE4","title":"Genetics and HIV-1 Protease Inhibitors","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2006-09","conditions":"HIV","enrollment":31},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01367236","phase":"PHASE4","title":"Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"HIV, Impaired Cognition","enrollment":60},{"nctId":"NCT00335322","phase":"PHASE4","title":"ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2007-02","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":329},{"nctId":"NCT01705574","phase":"PHASE3","title":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10-24","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":583},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT01599364","phase":"PHASE4","title":"Atazanavir/r + Lamivudine Dual Therapy","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2014-04","conditions":"Human Immunodeficiency Virus","enrollment":266},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01967940","phase":"PHASE3","title":"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10-25","conditions":"HIV, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":55},{"nctId":"NCT01384734","phase":"PHASE2","title":"HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-07-26","conditions":"Infection, Human Immunodeficiency Virus","enrollment":254},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01335698","phase":"PHASE3","title":"Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-05-27","conditions":"HIV","enrollment":160},{"nctId":"NCT01902186","phase":"PHASE4","title":"Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2014-09","conditions":"HIV Infection, Osteopenia","enrollment":4},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT02473328","phase":"PHASE2","title":"Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2015-06","conditions":"HIV-1 Infection","enrollment":90},{"nctId":"NCT02386098","phase":"PHASE2","title":"Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2015-07-08","conditions":"HIV Infections","enrollment":86},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT01351740","phase":"PHASE4","title":"Switch to Unboosted Atazanavir With Tenofovir Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"HIV Infection","enrollment":50},{"nctId":"NCT01479361","phase":"PHASE1","title":"Antiretroviral Drug Interaction Study in Volunteers With HIV","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2011-10-31","conditions":"HIV, PCP, Toxoplasmosis","enrollment":36},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT01099579","phase":"PHASE3","title":"PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-10-13","conditions":"HIV Infections","enrollment":82},{"nctId":"NCT01691794","phase":"PHASE4","title":"Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11-30","conditions":"HIV, Pediatric","enrollment":108},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT02641444","phase":"","title":"Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-04-13","conditions":"HIV","enrollment":5},{"nctId":"NCT01928407","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2011-02-23","conditions":"HIV-1 Infection, Immunosuppression-related Infectious Disease","enrollment":120},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT02697851","phase":"PHASE1","title":"Pharmacokinetic Effect of Evotaz/Microgynon Co-administration","status":"TERMINATED","sponsor":"St Stephens Aids Trust","startDate":"2016-07","conditions":"HIV","enrollment":13},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT00720590","phase":"NA","title":"Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2003-11","conditions":"Endothelial Dysfunction","enrollment":30},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT02154360","phase":"PHASE1","title":"Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-05","conditions":"HIV Infection","enrollment":12},{"nctId":"NCT01194856","phase":"PHASE4","title":"Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2010-10","conditions":"HIV Infection, Mitochondrial Dysfunction","enrollment":1},{"nctId":"NCT00931801","phase":"PHASE4","title":"BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2009-12","conditions":"HIV","enrollment":43},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atazanavir (Reyataz)","genericName":"Atazanavir (Reyataz)","companyName":"Germans Trias i Pujol Hospital","companyId":"germans-trias-i-pujol-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}